Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
wrong you never know the bottom and you never know a buyout
you especially
you buy over time and average
guaranteed buyout in the works they paid him in shares for the buyout under the table.
Thats the move. here are shares we paid you for yout buyout.
BUY ANYTHING YOU CAN> 100% buyout already done behind the scenes
1.5 million shares were sold into that announcement artifcially keeping price down
Buy anything you can
they will announce buyout along with the new rollout of the new name and issue shares at that point
yes. buyout in the works.
Always awarded options just before buyout.
Buy anything yoou can. load up and retire
Competitive Conditions
The entrenched industry leader within the robotic surgical market is Intuitive Surgical, Inc., manufacturer of several models of the da Vinci® Surgical System. Having entered the market in 2000, Intuitive Surgical’s product line now includes multiple generations of da Vinci multi-port robotic systems, as well as a new single-port da Vinci SP® model cleared by the FDA for urologic applications, with customer shipments that began in the third quarter of 2018. Specifically related to abdominal surgery, a new competitor in multi-port robotic surgery recently emerged, with TransEnterix Inc. receiving FDA clearance for its SenhanceTM Surgical Robotic System in October of 2017. In addition, Medrobotics Corporation has received FDA clearance for abdominal indications for its Flex® Robotic System with manual endoscopic instruments, which had previously been cleared for natural orifice (ENT) surgery. On February 13, 2019, Ethicon, Inc. (a division of Johnson & Johnson) announced that it had entered into a definitive agreement to acquire Auris Health, Inc., the maker of the MonarchTM surgical platform, for approximately $5.75 billion (including contingent payments). Further, there are a number of companies reported to be developing robotically-assisted surgical systems, including Medtronic, Inc., Verb Surgical Inc. (a collaboration between Alphabet Inc.’s Verily division (formerly, Google Life Sciences) and Ethicon, Inc., CMR Surgical Ltd. from the United Kingdom (Versius® surgical robotic system) and South Korea’s Meere Company Inc. (Eterne robotic system).
Any company with substantial experience in robotics or complex medical devices could potentially expand into the field of surgical robotics and become a future competitor.
probably a raise in funds.
or better you what the norm is.
its pumped up 2 days by traders so some mom and pops buy in then then they short it back down and try to scare the shares out of the people who just bought.
rinse and repeat
https://www.streetinsider.com/SEC+Filings/Form+40-F+TITAN+MEDICAL+INC+For%3A+Dec+31/15314853.html
page 14
you might be pulling a little too much
Usually need to call those in to broker because then they call over the international side and buy them for usa side.
you can trade the warrant w a lot of built in premium even if you dont want to exercise. over the next 2 years.
yes i suggesty buying as many as you can. 17$ usa
titan at 2 billion buy out at 70 million shares is 29$ a share.
that at only 2 billion. and gives you the luxury to sit back for 2 more years with feet up and not risk your 150k up front.
not to mention where they are priced now is a gift and they will trade at a permium
that way you dont have to tie up as much money. not to mention the can be traded when price appriciates for a premium and then you can buy shares on the open market if you choose at a lower price than the warrant exercise in 2021 if you so please
its a no brainer. they are pennies on the dollar to buy and hold for 2 years if you dont want to keep buying and spending larger wads.
no brainer load up on 2021 warrants.
last time i checked its 2019. the TTLLF warrants are 2021, and pennies on the dollar.
im not. i think you buy all you can and hold and retire.
cry about a stock who didnt even apply for FDA yet? LOLO
dude you are lost.
talk to hear youself.
buy and hold for the only reason to invest. FDA A PPROVED
no sales? stocks dont trade on fair maket value.
god you are a novice rookie
stick to your day job
trap you not me.
The is a 2-5 billion company next year. talk to us then
They usually have fake producs and stay on the pink
we are below reprice.
So im sure they will work vry hard.
maybe so. BUt you dont care what the price is pre fda anyone. I know i dont
maybe so. BUt you dont care what the price is pre fda anyone. I know i dont
short is working ill say that.
there is no reason for anyone to sell here excpet if they are traders.
is being played. so all you mom and pops sell shares so the instution can buy them all on the cheap and hold majority
buyout in the works.
cut and paste
THAT trxc dead cat bounce was nice so artificial
not really. Uncertain what? billion dollar potential and a few milly.
market cap is what the company raised this year. normal trading cap is 5-10x value
they control direction. as you see. sell 5k shares at times drops us 5% a pop and 20k shares buy hardly moves up.
on real big ass volume it can not be controlled. but anythnig under 150k volume easily managed the direction some larger holders want it to be in.
Some hold it down after taking a loss then to buy back in after 30 days bring it up then wash and repeaT. If you have a lot of shares and traders its easy to contorl
i dont control it. I do Know buy and hold I will make a shit load of money
keep in mind this stock is controlled and manipulated just an fyi. When they want to let it move they will. controlled all my float and traders
EARLY FDA GUARANTEED!
HUGEEE COVER THOSE SHORTS@!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
HUGEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE
Titan Medical Completes Preclinical Good Laboratory Practice Procedures With Its Single-Port Robotic Surgical System
8:43 AM ET, 07/18/2019 - Business Wire
TORONTO--(BUSINESS WIRE)--Jul. 18, 2019-- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that all procedures under Good Laboratory Practice (“GLP”) principles associated with the acute and chronic animal studies and human cadaver studies using its single-port robotic surgery system have been completed. The Company intends to announce the results of required follow-up to the chronic procedures by the end of August.
“We are pleased to have completed all of the planned GLP procedures necessary for our Investigational Device Exemption (“IDE”) application to the U.S. Food and Drug Administration (“FDA”),” said David McNally, Titan’s chief executive officer. “Anticipating positive results from the chronic study, we subsequently plan to submit the IDE application to the FDA during the current quarter. Meanwhile, we are proceeding with human factors studies that were previously planned for the second quarter and moved to the third quarter in order to accommodate the GLP procedures, which from a timing perspective, were our priority. All of this data, along with the confirmatory human data to be collected from studies under the IDE, is intended to support our planned 510(k) application for U.S. marketing clearance of our single-port robotic surgery system, and a concurrent application for the CE mark planned by year-end 2019.”
i hope they do
I am a pro i invest for 3-5 years. I will BAG big time on this.
Sticky money
WAKE UP!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
they have been testing behind the scenes big time to speed up the process.
where do you think all that momney was going.
HUGEEEEEEEEEEEEEEEE NEWS OUT !! CUMING